Bispecifics and multispecifics at Antibody Engineering 2026

Dec 13–16, 2026 San Diego, CA ~900 attendees Website

35 organizations at Antibody Engineering 2026 present work in bispecifics & multispecifics: 21 drug developers, 8 academic, government and non-profit bodies and 6 suppliers and service providers. Between them they bring 57 presentations to the program. Most represented: Xencor (4 on the program), AstraZeneca (3 on the program), Genentech (3 on the program). 14 of them have their own page in this guide. As of Sep 26, 2026.

All 153 organizations at Antibody Engineering 2026 →

Showing 1–11 of 35 organizations

Organization	Antibody Engineering 2026 Attendance
Xencor Pasadena, CA
xencor.com Biotech Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases.	Talk Sun Dec 13 1:00pm–1:15pm Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen Talk Sun Dec 13 4:15pm–5:00pm Moderated Panel Discussion with Session Speakers Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen Talk Mon Dec 14 8:00am–8:05am Co-Chairs' Welcome and Opening Remarks Keynote Presentations - Livestream · with Gyes Talk Mon Dec 14 10:55am–11:30am Jim Huston Science Talent Award and Presentation: Keynote Presentations - Livestream · with Dana-Farber Cancer Institute Talk Wed Dec 16 8:10am–8:15am Co-Chairs’ Remarks Track 2: Engineering Antibody Interfaces: Unlocking New Biology · with Dualitas Therapeutics Talk Wed Dec 16 9:15am–9:45am XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood. Bispecifics & multispecifics
AstraZeneca Cambridge, United Kingdom
astrazeneca.com Large pharma Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases.	Talk Sun Dec 13 11:00am–11:45am Career Path/Experiences Panel Discussion Early Career Scientist Session · with Macaw Therapeutics, Genentech Keynote Mon Dec 14 10:20am–10:55am From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients. ADCs & conjugates Talk Wed Dec 16 10:30am–11:00am CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions. Talk Wed Dec 16 2:10pm–2:15pm Co-Chairs' Remarks Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms · with Washington University School of Medicine Talk Wed Dec 16 2:15pm–2:45pm Expanding the Toolbox: Non-natural Amino Acids Enable Development of a CD30 Dual-payload ADC Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Genentech South San Francisco, CA
gene.com Large pharma Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines.	Talk Sun Dec 13 11:00am–11:45am Career Path/Experiences Panel Discussion Early Career Scientist Session · with Macaw Therapeutics, AstraZeneca Talk Mon Dec 14 2:30pm–3:00pm Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed. Bispecifics & multispecifics Talk Tue Dec 15 8:10am–8:15am Co-Chairs’ Remarks Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Johnson & Johnson Talk Tue Dec 15 8:15am–8:45am From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes. Protein engineering
Regeneron Tarrytown, NY
regeneron.com Large pharma Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform.	Talk Sun Dec 13 3:45pm–4:15pm From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule. Talk Mon Dec 14 5:15pm–5:45pm Targeting IgE Responses Track 2: Engineering Solutions for Accessing Difficult Targets Beyond oncology Talk Wed Dec 16 8:10am–8:15am Co-Chairs’ Remarks Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Rondo Therapeutics
University of Southampton Southampton, United Kingdom
southampton.ac.uk Academic Public research university whose Centre for Cancer Immunology works on antibody immunotherapy and Fc receptor biology.	Talk Mon Dec 14 2:25pm–2:30pm Co-Chairs’ Remarks Track 2: Engineering Solutions for Accessing Difficult Targets · with Macaw Therapeutics Talk Mon Dec 14 4:45pm–5:15pm Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation Adding chemical bridges between an antibody's two arms to lock its shape and make it switch on immune cells more strongly. Protein engineering Talk Tue Dec 15 8:10am–8:15am Co-Chairs' Remarks Track 2: Antibody Engineering for Proximity-Based Approaches · with Chai Discovery
RT Rondo Therapeutics Hayward, CA
Biotech Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors.	Talk Tue Dec 15 2:25pm–2:30pm Co-Chairs’ Remarks Track 1: Engineering and Biological Principles for Cell Engagers · with National Cancer Institute Talk Tue Dec 15 2:30pm–3:00pm Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs. Talk Wed Dec 16 8:10am–8:15am Co-Chairs’ Remarks Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Regeneron
City of Hope Duarte, CA
cityofhope.org Academic Cancer research and treatment center with a graduate school.	Talk Wed Dec 16 3:15pm–3:45pm MPACT: Engineering the Fc–FcγR Interface for Plug-and-Play, Mixed-Valency Multispecific Antibodies Using a chemical bond at a natural antibody contact point to snap extra targeting or immune-activating parts onto one antibody. Bispecifics & multispecifics Talk Wed Dec 16 4:15pm–4:45pm Turning up the Heat: Radioimmunoconjugates for Targeted Radiation Therapy Using antibodies and smaller antibody pieces to carry radioactive atoms that both image and irradiate tumors.
University of Michigan Ann Arbor, MI
umich.edu Academic Public research university in Ann Arbor, Michigan.	Talk Sun Dec 13 1:00pm–1:15pm Co-Chairs’ Remarks- Engineering Considerations for Candidate Selection and Developability Workshop 2: Engineering Considerations for Candidate Selection and Developability · with Atlas Venture NewCo Talk Tue Dec 15 3:00pm–3:30pm Dual-targeted Oligoshuttles Mediate Efficient Reduction of Neuronal Gene Expression after Peripheral Administration Antibodies that grab two receptors to cross into the brain and deliver gene-silencing strands into nerve cells. Bispecifics & multispecifics
Zymeworks
zymeworks.com Biotech Develops multispecific antibody therapeutics and antibody–drug conjugates using its Azymetric bispecific and other protein engineering platforms.	Talk Sun Dec 13 1:45pm–2:15pm Engineering Conditional Co-stimulation: Key Considerations for Developing Next-Generation T Cell Engagers What to get right, from target choice to safety testing, when building T-cell-recruiting antibodies with a built-in second signal. Bispecifics & multispecifics Talk Wed Dec 16 8:45am–9:15am Engineering Trispecific T Cell Engagers (TriTCEs) For Optimal Activity and Developability Antibodies that bind three things at once to give T cells an extra activating signal inside solid tumors. Developability & CMC
Twist Bioscience South San Francisco, CA
twistbioscience.com Reagents & consumablesEvent partner Synthetic DNA company whose biopharma unit provides antibody libraries and antibody discovery and optimization services.	Booth Exhibiting at Booth 201 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm Engineering for Better Bispecifics: Introducing the B-Body® Platform A two-target antibody design meant to assemble reliably, avoiding low yields and hard purification when production scales up. Bispecifics & multispecificsDevelopability & CMC Talk Wed Dec 16 7:30am–8:00am A High-Throughput Ecosystem to Power AI-Driven Antibody Discovery Building large custom variant libraries so computer-designed antibodies can be made and tested in the lab within weeks. Antibody discoveryAI & computational design
Chai Discovery San Francisco, CA
chaidiscovery.com Software & AI Builds AI models that predict molecular interactions and design antibodies de novo from a target epitope.	Talk Sun Dec 13 9:00am–9:10am Session Co-Chair Welcome and Opening Remarks Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers. with argenx Talk Tue Dec 15 8:10am–8:15am Co-Chairs' Remarks Track 2: Antibody Engineering for Proximity-Based Approaches · with University of Southampton